The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | Update on recent smoldering multiple myeloma trials
Clinical trials in smoldering multiple myeloma (SMM) have produce many exciting results, with new drug approvals and standards of care arising from recent studies. We got an update on the latest SMM trials from Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France. Dr Mateos explains how there are more than 50 such trials ongoing currently, which are typically lenalidomide-dexemethasone based with the addition of a novel agent such as elotuzumab or ixazomib. She also describes a daratumumab-based study with curative intent that is running.
